UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 15, 2015
United Therapeutics Corporation
(Exact Name of Registrant as Specified in its Charter)
Delaware |
|
000-26301 |
|
52-1984749 |
(State or Other |
|
(Commission |
|
(I.R.S. Employer |
Jurisdiction of |
|
File Number) |
|
Identification Number) |
Incorporation) |
|
|
|
|
1040 Spring Street |
|
|
Silver Spring, MD |
|
20910 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (301) 608-9292
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01. Regulation FD Disclosure.
On October 15, 2015, United Therapeutics Corporation issued a press release announcing that its Board of Directors has authorized a share repurchase program of up to $500 million of its common stock. Shares repurchased under this program will be held in treasury. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained in Item 7.01 to this Current Report on Form 8-K, and Exhibits 99.1 attached hereto, shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Exhibits
(d) Exhibits |
| |
|
|
|
Exhibit No. |
|
Description of Exhibit |
|
|
|
99.1 |
|
Press Release dated October 15, 2015 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
UNITED THERAPEUTICS CORPORATION | |
|
| |
|
| |
Dated: October 15, 2015 |
By: |
/s/ Paul A. Mahon |
|
Name: |
Paul A. Mahon |
|
Title: |
General Counsel |
Exhibit 99.1
Contact: James Edgemond
Phone: (301) 608-9292
E-mail: jedgemond@unither.com
UNITED THERAPEUTICS ANNOUNCES
ADDITIONAL $500 MILLION SHARE REPURCHASE PROGRAM
Silver Spring, MD and Research Triangle Park, NC, October 15, 2015: United Therapeutics Corporation (NASDAQ: UTHR) today announced that its Board of Directors authorized the repurchase of up to an additional $500 million of the companys common stock. This program will become effective on January 1, 2016, and will remain open for up to one year. Purchases may be made in the open market or in privately negotiated transactions from time to time as determined by United Therapeutics management and in accordance with the requirements of the U.S. Securities and Exchange Commission.
We are pleased to continue our track record of returning value to our shareholders via substantial stock repurchases, remarked Martine Rothblatt, Ph.D., United Therapeutics Chairman and Co-Chief Executive Officer.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. [uthr-g]
Forward-looking Statements
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding future repurchases of shares of our common stock. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission that could cause actual results to differ materially from anticipated results. These risks and uncertainties include, among others, our ability to successfully execute repurchases on favorable terms, and such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 15, 2015, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.